ReviewAntiviral therapy2011
Preventing and treating secondary bacterial infections with antiviral agents.
Review in Antiviral therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Pooled it
- Swine influenza A virus infection sets the local immunological landscape in subsequent infection with porcine reproductive and respiratory syndrome virus.Veterinary research · 2025Article
- Insights from respiratory virus co-infections.World journal of virology · 2024Review
- Human monoclonal antibodies protect against viral-mediated pneumococcal superinfection.Frontiers in immunology · 2024Article
- Bacterial and Viral Co-Infection in the Intestine: Competition Scenario and Their Effect on Host Immunity.International journal of molecular sciences · 2022Review
- Increased virus dissemination leads to enhanced lung injury but not inflammation during influenza-associated secondary bacterial infection.FEMS microbes · 2022Article
- Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.Virulence · 2021Article
- Impact ofMicroorganisms · 2020Article
- Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS.Research square · 2020Article
- Secondary Bacterial Infections in Patients With Viral Pneumonia.Frontiers in medicine · 2020Review
- Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?Frontiers in microbiology · 2020Review
- Application of Optimal Control to Influenza Pneumonia Coinfection with Antiviral Resistance.Computational and mathematical methods in medicine · 2020Article
- Refinement of estimates of mortality risk using the Radiologic Severity Index in hematologic malignancy patients with respiratory syncytial virus infection.Transplant infectious disease : an official journal of the Transplantation Society · 2019Article
- How Viral and Intracellular Bacterial Pathogens Reprogram the Metabolism of Host Cells to Allow Their Intracellular Replication.Frontiers in cellular and infection microbiology · 2019Review
- Host-pathogen kinetics during influenza infection and coinfection: insights from predictive modeling.Immunological reviews · 2018Review
- The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection.Scientific reports · 2018Article
- The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.Viral immunology · 2018Review
- Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling.PLoS pathogens · 2018Review
- A DNA aptamer efficiently inhibits the infectivity of Bovine herpesvirus 1 by blocking viral entry.Scientific reports · 2017Article
- Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza.Journal of pharmacokinetics and pharmacodynamics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data, but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of influenza. The association of secondary bacterial pathogens with fatal pneumonia during the recent H1N1 influenza pandemic highlights the need for new development in this area. Basic and clinical research into viral-bacterial interactions over the past decade has revealed several mechanisms that underlie this synergism. By applying these insights to antiviral drug development, the potential exists to improve outcomes by means other than direct inhibition of the virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.